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ABSTRACT
Pseudogenes, in the case of protein-coding genes,
are gene copies that have lost the ability to code for
a protein; they are typically identified through anno-
tation of disabled, decayed or incomplete protein-
coding sequences. Processed pseudogenes (PCgs)
are made through mRNA retrotransposition. There is
overwhelming genomic evidence for thousands of
human PCgs and also dozens of human processed
genes that comprise complete retrotransposed
copiesofothergenes.Here,wesurveyforaninterme-
diate entity, the transcribed processed pseudogene
(TPCg), which is disabled but nonetheless tran-
scribed. TPCgs may affect expression of paralogous
genes, as observed in the case of the mouse
makorin1-p1 TPCg. To elucidate their role, we identi-
fied human TPCgs bymapping expressed sequences
onto PCgs and, reciprocally, extracting TPCgs from
known mRNAs. We consider only those PCgs that
are homologous to either non-mammalian eukaryotic
proteins or protein domains of known structure, and
require detection of identical coding-sequence dis-
ablements in both the expressed and genomic
sequences. Oligonucleotide microarray data provide
further expression verification. Overall, we find 166–
233 TPCgs(  4–6% of PCgs). Proteins/transcripts
with the highest numbers of homologous TPCgs
generally have many homologous PCgs and are
abundantly expressed. TPCgs are significantly over-
representednearboththe50 and30 endsofgenes;this
suggests that TPCgs can be formed through gene–
promoter co-option, or intrusion into untranslated
regions. However, roughly half of the TPCgs are loc-
ated away from genes in the intergenic DNA and thus
may be co-opting cryptic promoters of undesignated
origin.Furthermore,TPCgsareunlikeotherPCgsand
processedgenesinthefollowingways:(i)theydonot
show a significant tendency to either deposit on or
originate from the X chromosome; (ii) only 5% of
human TPCgs have potential orthologs in mouse.
This latter finding indicates that the vast majority
of TPCgs is lineage specific. This is likely linked to
well-documented extensive lineage-specific SINE/
LINE activity. The list of TPCgs is available at:
http://www.biology.mcgill.ca/faculty/harrison/tppg/
bppg.tov (or) http:pseudogene.org.
INTRODUCTION
Thesearch fornovel functional elementsin the human genome
is imperative and ongoing (1–3). Pseudogenes (gene copies
that have lost their protein-coding ability) are a form of
sequence of potential functional utility (4). Substantial pro-
gress has been made in the annotation of pseudogenes (5–11).
There may be twice as many pseudogenes (derived from
protein-coding genes) in the human genome as protein-
coding genes (6–10).
Pseudogenes (derived from protein-coding genes) are typ-
ically ‘diagnosed’ through searching for the ‘symptoms’ of a
lack of protein-coding ability. These symptoms include: frame
disablement (from premature stop codons and frameshifts),
coding sequence decay (typically detectable through examina-
tion of non-synonymous and synonymous substitution rates)
or incompleteness (either from sequence truncation or from
thelossofessentialsignalsfortranscription,splicingandtrans-
lation) (6–10). Processed pseudogenes (PCgs) are made
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genomic evidence for thousands of PCgs in mammals
(5–10). Similarly, dozens of processed genes (i.e. genes
made by retrotransposition of the complete sequence of
other genes) have arisen in both the mouse and human gen-
omes (12,13). This mass gene retrotransposition may arise, at
least in part, as a by-product of long interspersed element
(LINE) retrotransposition (14). Retrotransposition is clearly
an active process in mammalian gene evolution (15). Here,
we search for an intermediate type of retrotransposed gene
sequence: the transcribed processed pseudogene (shortened as
TPCg), which is a PCg that is disabled but nonetheless tran-
scribed.
Historically, there have been several isolated reports of
transcribed pseudogenes, of either the duplicated or the pro-
cessed form (16–21). Two recent studies have demonstrated
that such transcribed pseudogenes canregulate transcription of
homologous protein-coding genes. Transcription of a pseudo-
gene in Lymnea stagnalis, that is homologous to the nitric
oxide synthase gene, decreases the expression levels for the
gene through formation of a RNA duplex; this is thought to
arise via a reverse-complement sequence found at the 50 end of
the pseudogene transcript (20). In a second example, transcrip-
tion of the makorin1-p1 TPCg in mouse was required for the
stability of the mRNA from a homologous gene makorin1
(21). This regulation was deduced to arise from an element
in the 50 areas of both the gene and the pseudogene (21).
In addition to helping to elucidate such regulatory roles,
annotation of TPCgs will further add to our understanding
of the dynamics of gene evolution through retrotransposition
(15). Also, it is crucial to annotate TPCgs correctly as a part of
the ongoing process of correct cDNA/expressed sequence tag
(EST) mapping during genome annotation, and for more
accurate interpretation of microarray expression data
(22,23). Here, we have performed a data-mining expedition
for human TPCgs using a rigorous method that applies strin-
gent ﬁlters to avoid data pollution. TPCgs have a markedly
distinct distribution in the genome when compared with other
PCgs and processed genes. A key result is that TPCgs are
signiﬁcantly likely to insert near the 50 and 30 ends of
genes, implying that TPCgs can be generated by co-option
of promoter elements or by intrusion into untranslated regions
(UTRs) as ‘molecular passengers’. Also, we ﬁnd that the
vast majority of TPCgs are human-lineage speciﬁc compared
with mouse.
Definitions and terms
An mRNA can be reverse transcribed and re-integrated
into the genomic DNA, possibly as a by-product of LINE-1
retrotransposition(14). The parent gene ofthe mRNAneed not
be on the same chromosome as the retrotransposed copy. Such
a retrotransposed mRNA has three possible fates in the
present-day genome: (i) formation of a non-transcribed
PCg, (ii) formation of a TPCg or (iii) formation of a processed
gene (or part of a gene).
A PCg can be deﬁned as any disrupted, decayed or incom-
plete copy of a gene that has arisen through such retrotrans-
position. In the process of evolution, PCgs accumulate
disablements (frameshifts and premature stop codons) in
their apparent coding sequences. Procedures to annotate
PCgs using disablement detection have been described previ-
ously (4,5,7), and serve as the basis for the present analysis.
Operationally, a TPCg is deﬁned as a PCg for which
an expressed sequence is mappable across any of its
coding-sequence disablements, i.e. the disablement occurs
in both the expressed sequence and the genomic sequence
(see Methods for details).
A processed gene is any undisrupted retrotransposed copy
of a gene that also has low Ka/Ks values indicative of selection
pressure on coding ability (see Methods for details).
Each of our TPCgs has >1 disablement veriﬁed by align-
ment of the expressed sequences to genomic DNA, in a region
ofthe TPCgthatmapstoaknownstructuralproteindomain, or
to a protein sequence that is conserved in non-mammalian
eukaryotes. This three-level veriﬁcation procedure (genome:
transcript:protein) is termed triple alignment. Each veriﬁed
disablement has an estimated probability of being the result
of a sequencing error of <10
 6, since the error rate for the
genomic sequence build is <10
 4 (24) and the error rate for
cDNAs/ESTs is <10
 2 (25,26). We made a subset of TPCgs,
termed the C set, which has further evidence of lack of coding
ability. These have: (i) no continuous segment of sequence
that can code for a protein domain (as deﬁned in Methods);
(ii) high Ka/Ks values (>0.5).
As it is possible that a fraction of the TPCgs that map to
introns arise from intron retention in cDNAs or ESTs in the
source expressed sequence data, we analyzed all of the data
both including and excluding the 67 TPCgs that map to introns
(see Table 3 and below). Our results are unaffected by such
potential contamination, as explained below.
METHODS
Detection of TPCgs
(i) Mapping expressed sequence data onto existing PCgs
annotations. PCgs were annotated previously using a method
based on the detection of disabled protein homology in
genomic DNA (4,5,7). We mapped >6200 of these onto
human genome build 34 (from http://www.ensembl.org),
through detection of 100% nucleotide sequence matches,
removing overlap with coding exons. For each PCg, the
genomic sequence was extracted, both with and without a
6000 nt extension added on to either end to allow for homo-
logy matching to ‘pseudo-UTR’ regions. (These sets of
genomic DNA are named genPCg and genPCg+/ 6000.)
Three sources of expressed sequences (Refseq mRNAs, Uni-
gene consensuses, and ESTs from dbEST) were downloaded
from http://www.ncbi.nih.gov. They were mapped onto gen-
PCg and genPCg+/ 6000, using BLASTN with low-complexity
masking (E-value < 10
 10, minimum match length 100 nt)
(27,28). From the resulting signiﬁcant matches, those that
align with >95% identity were used to generate a second
BLASTN search against genPCg and genPCg+/ 6000,
but this time without low-complexity masking, to insure
correct sequence identity. Matches to both genPCg and
genPCg+/ 6000 with >99% identity over >0.998 of the length
of the expressed sequence were then extracted. These
expressed sequence matches were ﬁltered to insure that
they match more signiﬁcantly to the PCg than to any homo-
logous gene. The matching expressed sequences were then
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that >1 disablement (frameshift or premature stop codon) in
the PCg occurs in both the genomic sequence and expressed
sequence. Each disablement veriﬁed in this way has an estim-
ated probability of being the result of a sequencing error of
<1 · 10
 6; this is because the genomic sequence error rate is
<1 · 10
 4, and the cDNA/EST sequencing error rate is <1
·10
 2.
(ii) Extraction of PCgs that are in Refseq mRNAs. All human
Refseq entries corresponding to known mRNAs (total = 20
741) were compiled from data downloaded from the NCBI
website(http://www.ncbi.nih.gov).These were compared with
all known, non-fragmentary human proteins in the SWIS-
SPROT database (30), using a modiﬁcation of the disabled
protein homology-based procedure developed previously for
PCg annotation (4,5,7,31–33). To insure that all of the can-
didate TPCgs in Refseq mRNAs map to a single continuous
piece of genomic DNA, we extracted the appropriate mRNA
subsequences and mapped them to the human genome using
BLASTN. Those segments that matched over their complete
length exactly were retained. The resulting TPCg data were
then ﬁltered along with those generated in (i), as detailed in
(iii) below.
(iii) Filtering the (transcribed) PCg data. We applied a set of
ﬁlters to insure that we were compiling a bona ﬁde list of
TPCgs. All TPCg data sets were ﬁltered as follows:
(a) Removal of homologies to purely hypothetical proteins or
fragmentary proteins: TPCgs based only on homology to
predicted reading frames or reading-frame fragments
were removed through BLASTP comparisons (E-value
< 10
 4) against a library of hypothetical or fragmentary
proteins from SWISSPROT (30). These are removed
because their disablements may be erroneous (which is
inappropriate for the method employed here). Also, they
may be inaccurately dated (values for Ks, Ka, etc., may be
incorrect).
(b) Verification that the disablements are in conserved parts
of a known protein sequence or domain: We verified that
the disablements examined are in known conserved parts
ofsequences,asdetailedbelow.Thislistoffiltershasan‘if-
else-if-else-if’ structure:
(1) First, we assigned protein structural domains to the
TPCgs, by comparing them with the ASTRALSCOP
95% identity set of protein domains (34), using
BLASTP (27) (E-value < 10
 4). The total assigned
TPCg subsequence was determined (from the most N-
terminal residue that was assigned to a domain, to the
mostC-terminal).Thisassignedsubsequencewascon-
sidereddisabled,ifaframeshiftorstopcodonoccurred
>10residuesinfromeitherterminus.Thisaccountsfor
 54% of TPCgs.
(2) Otherwise, secondly, TPCgs not meeting criterion (1)
werecheckedmanuallyforoccurrenceofdisablements
in conserved domains using the InterPro (http://
www.ebi.ac.uk/interpro) and CDD (http://www.ncbi.
nlm.nih.gov/Structure/cdd/cdd.shtml)domain annota-
tion tools.
(3) Otherwise, thirdly, TPCgs not meeting criterion (2)
(<10%ofthesequences)werecheckedfordisablement
within a part of the sequence that is conserved in other
mammals, and in >1 non-mammalian species, using
BLASTP (E-value < 10
 4).
(c) Removal of candidates with small introns: Putative PCgs,
TPCgs, and the expressed sequences that match them,
were filtered for small intron sequences. A library of
introns of <1000 nt was made from genes on human gen-
ome build 34. TBLASTN (27) was used to annotate any
significantmatches totheseintrons of>0.80oftheir length
(E-value < 10
 4). Any such matches could either be from
intronsinanaberrantcDNAorbeapreviouslydisregarded
small intron in the genome. Some additional examples of
TPCgs that map to introns may arise from intron retention
in cDNAs or ESTs; however, the main points of the ana-
lysisreported inthis paper are unaffected by suchpotential
contamination, as explained below.
(d) Removal of possible duplications of single-exon genes and
largeexons:Wewishedtoinsurethattherewerenosingle-
exon gene duplications in our PCg and TPCg sets. To do
this, all PCgs and TPCgs were compared using BLASTP
(E-value<10
 4),tothesetofproteinsforbuild34(remov-
ing those whose genes overlap putative PCgs) (27). All
PCgs and TPCgs that had closest-matching homologies
to single-exon proteins were removed. Furthermore, we
insured that they aligned to their closest-matching homo-
logoushumanproteinsaroundatleastone‘exonseam’,i.e.
a position in a protein sequence that corresponds to an
intron–exon boundary. This exon seam filter insures that
the pseudogenes considered are processed, and is particu-
larly useful for removing homologies to genes with large
exons (e.g. some zinc-finger-containing proteins).
(e) Filtering for processed genes: All TPCgs were filtered for
overlap with annotated processed genes (resulting in the
removal of only one putative TPCg).
After applying these rigorous ﬁlters, we had 3418 PCgs
(both transcribed and non-transcribed), and 233 TPCgs, 218
from mapping expressed sequences to PCgs and 15 from PCg
extraction from Refseq mRNAs. Almost half (97/233, 42%)
of the TPCg set represent 100% exact matches of expressed
sequences to PCgs. Restricting analysis to just these matches
doesnotaffectanyofthemaintrendsandresultsreportedhere.
Making an obviously decayed C set of TPCg sequences
We derived a ‘core set’ of TPCgs that have further evidence of
coding-sequence decay. These are dubbed the C set (totaling
177/233, 76%). This set is the union of the following two
subsets: (i) TPCgs without continuous segment of sequence
that can code for a protein domain (106/233 TPCgs, 45%) or
(ii) TPCgs with high Ka/Ks values (>0.50) indicative of lack
of coding ability (127/233 TPCgs, 54%).
(i) Lack of protein domain coding ability. We parsed each
TPCg into subsequences according to the positions of its dis-
ablements. If all subsequences could be labeled as ‘unlikely
to code for a protein domain’, then the TPCg was included in
the C set. This resulted in inclusion of 106 TPCgs in the C set.
We labeled a subsequence as ‘unlikely to code for a protein
domain’ if:
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non-cysteine-rich protein domains in the ASTRALSCOP
40% identity set have sequence lengths >32 residues (34).
Cysteine-rich domains (which are likely disulfide-bridged
or metal-chelating) are defined as having cysteine concen-
tration<0.077/residue,avaluesuggestedbyabimodalityin
cysteine concentration, in surveys of cysteine and cystine
occurrence in proteins (35,36). Condition (a) was not
applied to any fragments that were adjudged cysteine-rich.
(b) It contained a disrupted SCOP domain, as defined in part
(iii)(b)(1)above.Suchfragmentsarelikelynottoconstitute
alargeenoughfragment;thereasoningbehindthiscriterion
is that evolution has defined and refined the integrity of a
body of recurrent folding units (protein domains) (34), and
we can therefore use their disruption to evaluate whether
a piece of sequence is no longer protein-coding.
(ii) Ka/Ks analysis. We calculated the Ka/Ks values for whole
TPCgs, using the Yang and Nielsen method in PAML (37),
using the present-day gene sequence to compare against the
pseudogene, as described previously (7). Also, similarly, we
calculated Ka/Ks values for subsequences of TPCgs( >50 resi-
dues) derived byparsing atdisablementpositions.This parsing
allows for the possibility that some of the pseudogene sub-
sequences have coding ability, while others do not, i.e. we can
test for a coding ability ‘imbalance’. From these Ka/Ks calcu-
lations,we foundthatonly 4%ofbothPCgsand TPCgshave
two adjacent regions where one is <0.25 (potentially coding)
and the other >0.5 (potentially non-coding), indicating that
such imbalance is rare. From consulting independent analysis
of populations of human genes and PCgs (6), we ascertained
that for a threshold value of Ka/Ks > 0.5, >95% of sequences
are predicted to be PCgs and not genes. We use this as the
expectationforthe distributionofPCgsingeneral. Calculation
of Ka/Ks values for gene/pseudogene pairs errs on the side of
under-estimation of coding-sequence decay (7).
Conservation of TPCg in mouse
For each human TPCg, we searched against potentially ortho-
logous mouse TPCgs. These ‘moTPCgs’ were derived by
mapping expressed sequences (Refseq mRNAs, Unigene con-
sensus sequences and ESTs) for mouse onto a previously
derived set of mouse PCgs (8), in a similar manner to the
human mappings (see above). These were pooled with any
existing moTPCg annotations, and a small number of mouse
genes that might be potentially misannotated moTPCgs.
A potentially orthologous moTPCg was required to match
>0.5 of the length of the human TPCg (for BLASTP matches,
E-value < 10
 4), and to share the same closest-matching
human protein with any potential human TPCg homologs.
We did not require that the retrotranspositions be in syntenic
positions, since orthologous gene retrotranspositions are not
necessarily syntenic (38).
Processed genes
We mapped an independently derived list of processed genes
(13) to human genome build 34. In addition to the criteria in
(13), we required Ka/Ks values <0.25, and coverage of >0.95
of the parent gene’s length. Any examples that overlap the
TPCg data set of annotations were removed; vice versa, any
TPCgs that have Ka/Ks < 0.25 and cover >0.95 of their parent
gene were deleted from the TPCgs list. Our deﬁnitions give
two distinct sets of processed genes and TPCgs; naturally, we
miss some sequences that cannot be classiﬁed as either a TPCg
or a processed gene.
RESULTS AND DISCUSSION
Number of TPCgs
In total, we found 233 human TPCgs (Table 1). These TPCgs
form a subset of 3418 previous PCg annotations that were
mapped to build 34 of the human genome (7). These PCgs
were ﬁltered in the same way as the TPCgs (from a starting
total of  6200), to remove predicted reading frames, retained
introns andpotential duplicationsofsingle-exon genes orlarge
exons. Using these data, we can estimate that  6% (218/3418)
ofPCgsareTPCgs.Anadditional15TPCgswerederivedfrom
a reciprocal process of searching for PCgs in known Refseq
mRNAs, followed by subsequent mapping to the genome.
A small fraction of the TPCgs (8%) corresponds to known
Refseq mRNAs (Table 1). About a third are supported by
Unigene consensus sequences, with a large fraction (71%)
matching individual ESTs [of this last group, about a quarter
( 23%) are supported by a Refseq mRNA or a Unigene con-
sensus; Table 1]. We sought additional expression veriﬁcation
Table 1. Summary of numbers of TPCgs
Set or subset of TPCgs Total number Total number (without
those mapped to introns)
Mappings to existing pseudogene annotations 218 154
Pseudogene extraction from Refseq mRNAs 15 12
Total TPCgs 233 166
Expressed sequence support
TPCgs that are supported by Refseq mRNAs 18 (8%) 16 (10%)
TPCgs that are supported by Unigene consensus sequences 74 (32%) 50 (30%)
TPCgs that are supported by dbEST expressed sequence tags 167 (72%) 111 (67%)
TPCgs that are supported by dbEST expressed sequence tags and by either
a Refseq mRNA or a Unigene consensus
38 (16%) 25 (16%)
TPCgs that are additionally supported by oligonucleotide microarray data 75 (32%) 53 (32%)
Further evidence of decay
TPCgs that have no continuous segment likely to code for a protein domain 106 (45%) 70 (42%)
TPCgs that have Ka/Ks > 0.5 127 (54%) 88 (53%)
C set (TPCgs that have no continuous segment likely to code for a
protein domain or Ka/Ks > 0.5)
177 (76%) 123 (74%)
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composed of  52 million 36mers (23). These microarrays
were applied to probe the transcriptionally active regions of
the human genome, in a strand-sensitive way. Using the same
data and statistical method (i.e. a sign test) for scoring the
genes’ transcriptional activity (22,23), we found that 75/233
(32%) TPCgs were transcriptionally active in liver (P < 0.05)
(Table 1). In comparison, 64% of genes from RefSeq mRNAs,
57% of Ensembl annotated genes (39), and 35% of genes
predicted with the program GENSCAN (40), were found to
be transcribed in liver.
TheCsetofmoreobviouslydecayedTPCgscomprises76%
of the total population; 45% of TPCgs having no continuous
segmentlikelytocodeforaproteindomain,and54%ofTPCgs
having Ka/Ks > 0.5 (Table 1). Obvious degradation of the cod-
ing sequences is demonstrated for this set from analysis of
protein-domain mapping and Ka/Ks (see Methods). Addition-
ally, other factors (not examined in the present analysis) are
expected to cause lack of coding ability in TPCgs or arise as
further consequences. It is likely that TPCgs will not have
appropriate start codon context (41), therefore leading to little
or no efﬁcient translation initiation. Also, those TPCgs that are
inserted into 30-UTRs of mRNAs will be unlikely to become
protein-coding through being downstream of a clearly deﬁned
coding sequence (although it is conceivable that they may be
translatableinthe50-UTR).Furthermore,aconsequenceofany
frameshift in a sequence is the likelihood of an additional 20
residues or so of non-coding DNA, added onto the end
of the sequence truncation (on average, in randomly picked,
conceptually translated intergenic DNA, a stop codon will
appear  20 residues downstream of any starting point); such
additional sequence may lead to aggregation or misfolding in
the cell.
The proportions of TPCgs break down in a similar fashion
to that just described above for the total data set, when the
67 examples that map to introns are removed (Table 1).
Closest matching human proteins for TPCgs
TPCgs were grouped according to their closest-matching
human protein (Table 2). Each table entry represents a single
‘parentgene’.ThetotalcountsarealsoshownfortheTPCgsthat
do not map to introns (in square brackets, Table 2). There are 4
human proteins that have >4 homologous TPCgs. The highest
numberofTPCgs(5)occurforcyclophilinA,whichisrequired
for cis-peptide isomerization (42). All of these proteins arise
from highly expressed mRNAs. They also occur in the top 20
proteins when apportioning all PCgs, in the same way (7).
TPCg position relative to genes and the implications
for their expression mechanisms
A number of mechanisms for TPCg expression are plausible.
First, TPCgs may co-opt nearby promoter elements of
protein-coding genes. Secondly, they may intrude into the
UTRs of another mRNA, as a sort of ‘molecular passenger’.
Thirdly, they may make use of cryptic promoter elements in
the intergenic DNA; such promoter elements may have ori-
ginated from transposable elements, or from genomic duplica-
tion of genic promoter regions, or sporadically (de novo).
Such mechanisms for TPCg expression may have a bearing
on their overall positional distribution in the genome relative
to genes. To investigate this, we classiﬁed the TPCgs into
those that: (i) overlap existing coding-sequence exons;
(ii) appear inserted in introns; (iii) are inserted in a 3000 or
10 000 nt region 50 to annotated genes; (iv) are inserted in a
3000 or 10 000 nt region 30 to annotated genes.
Table 3 summarizes these data. A minor proportion (8%) of
TPCgs entail gene coding-sequence annotations, i.e. they are
erroneously annotated reading frames. There are 67 TPCgs
that map to introns (Table 3); it is unclear how many of these
may arise from intron retention in cDNAs or ESTs. Expecta-
tions based on random insertion in the genome were calculated
for classes (ii) to (iv). We focus on (iii) and (iv) in particular.
TPCgs are signiﬁcantly more likely than random (P < 0.01,
chi-squared tests) to be inserted in the regions 50 and 30 of
annotated genes; this effect is most obvious in the 3000 nt
regions 50 and 30 to genes, but is still signiﬁcant up to 10 000 nt
in either direction (Table 3). Similar results are observed for
the C set of more obviously decayed TPCgs. The enrichment
of TPCgs observed in the 50 and 30 areas of genes can be seen
as a simple logical consequence of randomly inserted PCgs
having an increased probability of being transcribed, and is
clear support for either co-option of genic promoter elements,
or insertion into UTRs as molecular passengers, leading to
TPCg expression. This result is also unaffected by possible
contamination from intron retention in cDNAs/ESTs, as, in
general, PCgs are signiﬁcantly under-represented in introns
(Table 3); if one assumed that, in the extreme, all of the TPCg
mappings near the 50 and 30 ends of genes were actually
mappings to introns, then this would make their over-
representation even more signiﬁcant. The general dearth of
PCgs in introns may be a reﬂection of an overall genomic
tendency for a lack of retroelement insertion in introns (43).
Roughly half of the TPCgs are located away from genes
(>10 000 nt 50 and 30 to genes, and overlapping neither an exon
nor an intron; Table 3). These thus may be co-opting cryptic
promoters of unknown origin in the intergenic DNA, such as
those derivable from transposable elements.
In summary, the distribution of TPCgs in the vicinity of
genes is signiﬁcantly different from that observable for other
non-transcribed PCgs (that have no transcription evidence),
and for processed genes in the following ways (Table 3):
(i) TPCgsaresignificantlyover-representedinthe10000nt50
and 30 to genes, whereas other PCgs and processed genes
are not;
(ii) Other PCgs are significantly over-represented in inter-
genicDNAandsignificantlyunder-representedinintrons,
and processed genes are significantly under-represented
in introns; TPCgs now show such trends for introns or
Table 2. Human proteins with four or more homologous TPCgs
Number
a Name of human protein
b
5 [4] Peptidyl-prolyl cis-trans isomerase A (Cyclophilin A)
[P62937]
4 [3]
4 [3]
4 [3]
Prohibitin [P35232]
40S ribosomal protein S12 [P25398]
Actin, cytoplasmic 2 (Gamma-actin) [P63261]
Glyceraldehyde-3-phosphate dehydrogenase
[P04406, P00354]
aThetotalsinsquarebracketsareforwhenthosemappingtointronsareremoved.
bThe Swissprot accession numbers are given in square brackets.
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genes (Table 3). The reasons for this are unclear; there
may be a compositional effect, similar to the relationship
between genomic G+C content and ribosomal-protein
PCgs insertion, observed previously (44).
We examined the distribution of 20 TPCgs that are directly
mappable onto known Refseq mRNAs. Thirteen of these over-
lap an erroneously predicted open reading frame, and two are
already annotated as transcribed pseudogenes.None of the ﬁve
remaining TPCgs are inserted in the 50-UTR of a messenger
RNA. One explanation for this absence in 50-UTRs is that a
TPCg would introduce upstream ORFs that interfere with
translation initiation (41). The ﬁve TPCgs inserted in the
30-UTRs of mRNAs are all in the forward direction (i.e.
they are all on the same DNA strand as the annotated coding
sequence). An example of this is discussed below. In addition,
we checked the list of TPCgs3 0 to annotated genes and within
3000 nt of the end of the coding sequence (Table 3), for
additional examples of this ‘passenger’ phenomenon, through
manual examination of cDNAs or ESTs for the 50 genes, but
could ﬁnd no further examples of cDNAs with polyadenyla-
tion signals to deﬁne the end of the mRNA. Such analysis is
complicated by the fact that, in some cases, it may not be
possible to distinguish between the original polyadenylation
signal of the gene, and an inserted polyadenylation signal
arising from the TPCg.
Distribution on chromosomes
Analysis of the distribution of processed genes in the human
and mouse genome has indicated that the X chromosome is a
marked outlier, both for processed gene deposition onto the X
chromosome and origination from X (13). A similar outlier
preference was observed for PCg deposition onto the X chro-
mosome (but not origination from X) (13). These phenomena
may be due to selection pressures to compensate for X-
chromosome inactivation during spermatogenesis, in com-
binationwith someunaccounted-formutationalbiases (13,38).
To compare with this previous analysis, we examined the
distribution of TPCg ‘parent genes’ on each chromosome, and
also the distribution of the number of TPCgs per chromosome
(Figure 1A and B). Figure 1A indicates the data for origina-
tion of TPCgs, and Figure 1B shows the trend for deposition of
TPCgs onto each chromosome. In each case (origination and
deposition), the X chromosome is not an outlier. This may
indicate that, in general, TPCg formation is deleterious, unlike
processed gene and non-transcribed PCg formation, which are
arguably, by comparison, beneﬁcial and selectively neutral,
respectively. Interestingly, there is some outlier behavior for
TPCg origination from chromosome 12. The same result is
obtained, if the 67 TPCgs that map to introns are removed.
Search for potential orthologs in mouse
We investigated mouse/human cross-species conservation of
TPCgs, as an indicator of human-lineage speciﬁcity. The 233
human TPCgs were compared against a set of 215 putative
mouse TPCgs (moTPCgs) (see Methods fordetails).We found
that 5% (11/233) have potential orthologous TPCgs. Four
of these are for the metabolic enzyme, glyceraldehyde-3-
phosphate dehydrogenase, which is ubiquitously and highly
expressed, giving this sequence the status of a notable
‘parent gene’ for TPCgs (see also Table 2). If the human
and mouse TPCgs are not restricted to having the same
closest-matching human gene homolog, 28/237 (12%) have
potential orthologs.
These results suggest that a minor fraction of TPCgs could
be used in conserved functional roles in mammals. However,
given that  40% of human PCgs are conserved in the mouse
genome (8), these results imply that TPCgs are signiﬁcantly
under-conserved between human and mouse (P < 0.001 using
binomial statistics) compared with PCgs in general, and also
compared with processed genes (13), which are at most  20%
lineage-speciﬁc. The vast majority of TPCgs are thus human
lineage-speciﬁc compared with mouse; indeed, both Alus
(which are primate-speciﬁc) and PCgs can be made as by-
products of LINE retrotransposition (14), and have similar
overall age proﬁles in the genome (8). These results are
also evidence for a general evolutionary selection pressure
to delete TPCgs. This may be because they form a source
of transcriptional interference for adjacent genes or homolog-
ous genes. However, one must stress that, in the future,
increased cDNA coverage for both the mouse and human
Table 3. Position of TPCgs, other PCgs and processed genes relative to annotated genes
Categories of sequence grouped by position relative to genes Type of sequence
TPCgs Other PCgs Processed genes
Observed
number
a
Expected
number
b
Observed
number
a
Expected
number
b
Observed
number
a
Expected
number
b
Sequences that overlap gene annotations 18 (8%) — — — — —
Sequences mapped to introns of annotated genes 67 (28%) 79.7 693 (22%) 1100.0
{{ 3 (5%) 21.2
{{
Sequences <3000 nt 50 of start codon of annotated genes 20 (9%) 6.8
** 78 (0.7%) 93.6 5 (8%) 1.9
Sequences <10 000 nt 50 of start codon of annotated genes 36 (15%) 22.3
* 278 (9%) 307.8 7 (11%) 5.9
Sequences <3000 nt 30 of translation stop of annotated genes 22 (9%) 6.7
** 55 (1.7%) 92.3
{{ 0 (0%) 1.8
Sequences <10 000 nt 30 of translation stop of annotated genes 42 (18%) 22.2
** 241 (7%) 306.4
{{ 9 (14%) 5.8
Sequences that are in intergenic DNA
c 109 (47%) 129.8 2109 1371.7
** 43 31.4
aThesecategoriesarenotadditive,astheyarenotmutuallyexclusive,i.e.someTPCgmaybewithin10000ntofthe50 endofonegene,andbeintheintronofanother
gene or within 10 000 of the 30 end of a third gene.
bExpectedvaluesarecalculatedassumingrandominsertioninthewholegenome(withoutthegenomicDNAforannotatedgenes).Forsignificantover-representation,
** indicates P < 0.001, and
* indicates P < 0.01 for a chi-squared test (1 degree of freedom) using Yates correction (similarly,
{{ is used for significant under-
representation for P < 0.01).
cIntergenicDNAisdefinedasallofthegenomicDNAthatdoesnotcompriseexons,intronsortheregionsofgeneswithin10000ntofthetranslationstopandstartof
gene coding sequences.
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saturation in current databases of expressed sequences can be
demonstrated using some simple sampling analysis. Sampling
of TPCg-matching expressed sequences from random frac-
tional subsets of the total expressed sequence database used
in the present analysis (i.e. ESTs + Unigene consensuses +
Refseq mRNAs), indicates that we are not near ﬁnding all
of the TPCgs in the human genome (or, at least, those
discoverable through mapping of expressed sequences).
(This sampling analysis is presented in Supplementary
Figure 1.)
Examples of TPCgs
A TPCg derived from the prohibitin gene is shown in
Figure 2A. A prohibitin TPCg is inserted into the 30-UTR
of a Zn-ﬁnger-containing protein. Prohibitin is highly and
ubiquitously expressed, and is involved in inhibition of
DNA synthesis; its mRNA contains a putative functional
RNA element in its own 30 UTR (45). It is beyond the
scope of this present study to ascertain whether this RNA
element, in this TPCg, is intact, as it has not yet been char-
acterized extensively by mutational and biophysical analysis.
This TPCg is one of four that derived from the prohibitin
gene (Table 2).
The second example is derived from the precursor sequence
of mitochondrial 2-amino-3-ketobutyrate coenzyme A. The
crystal structure of the Escherichia coli homolog of this
enzyme is known (PDB code 1fc4a). We have indicated
how the ‘triple alignment’ of genomic sequence, EST and
known protein-domain sequence overlap (Figure 2B). The
protein chain is divided into colored segments, with each
disablement deﬁning a segment boundary. One can clearly
see that the triple alignment covers two disablements in
the TPCg.
CONCLUSIONS
Diverse efforts to map novel elements of potential functional
utility in our genome are ongoing (1–3). In the spirit of such
endeavors, we have derived a rigorous procedure for annot-
ating a speciﬁc novel type of element of potential functional
utility, the TPCg. Applying this method to the human genome,
we discovered 166–233 TPCgs, which represent  4–6% of all
PCgs (the lower total arises from setting aside any examples
that map to introns). One should point out that we might have
missed some TPCgs; e.g. those without extensive homology to
a coding sequence (i.e. those consisting largely of UTR homo-
logies), or TPCgs formed from single-exon and large-exon
genes, or TPCgs that are transcribed in a low-level beyond
detectability through EST/cDNA sequencing.
TPCgs are signiﬁcantly more likelyin regions close to the 50
and 30 ends of genes, compared with both a random insertion
model for them throughout the genome, and compared with
the distribution observed in general for PCgs. Furthermore, if
one assumes that these 50 and 30 regions are actually introns,
the signiﬁcance of the increased 50 and 30 density of TPCgs
improves. (This indicates that the increased 50 and 30 density is
not an artifact of intron retention in cDNA/EST libraries.) This
increased density provides evidence that TPCgs may be
expressed through co-option of genic promoter elements or
through insertion into UTRs as ‘molecular passengers’. Spe-
ciﬁc detailed evidence was found for molecular passengers in
the 30-UTRs of known mRNAs; an example of this derived
from the prohibitin gene was illustrated (Figure 2A). TPCgs
could thus also have a role as intermediates in protein-coding
sequence evolution. A reasonable hypothesis that can be fur-
ther investigated is that, TPCgs may represent a source of
evolutionary protein novelty, either as ‘molecular passengers’,
A
B
Figure 1. Origination and deposition of TPCgs for different chromosomes.
(A)OriginationofTPCgs:thisplotshowsthenumberofparentgenesofTPCgs
in a chromosome versus the chromosome size (in Mb). (B) Deposition of
TPCgs: this shows the number of TPCgs per chromosome versus
chromosome size (in Mb). Only retrotranspositions from one chromosome
to another are considered in each plot. The X chromosome is ringed. Note
thatforeachplotwehavecorrectedfortheprobabilityofXandYchromosome
inclusion in gametes [i.e. the size of X is multiplied by 0.75 and Y by 0.25; for
comparison see figure 1 in (13)].
2380 Nucleic Acids Research, 2005, Vol. 33, No. 8or as part of alternative splicings (46), through being tem-
porarily released from coding-sequence selection pressures
(31,47–50).Useofadditional sequence segmentsmayunderlie
the inﬂuence of the [PSI+] prion on phenotypic variability in
budding yeast (31,51); analogs of this phenomenon are pos-
sible in mammals.
Two examples of regulation by transcribed pseudogenes
of homologous genic transcripts have been observed
(20,21). Transcriptional analysis showed that the stability of
the makorin1 mRNA in mouse relies upon the expression of
its homologous makorin1-p1 TPCg, through the action of an
element at the 50 end of the makorin1-p1 sequence. However,
makorin1-p1 only seems to be conserved in one line of Mus,
and has not been found in the rat genome (52). In a second
example, transcription of a pseudogene in Lymnea stagnalis,
that is homologous to the nitric oxide synthase gene, decreases
expression levels for the gene; this is thought to arise via a
reverse-complement sequence found at the 50 end of the
pseudogene transcript (20). Alternatively, TPCgs near genes
or in UTRs may also exert a controlling/interfering inﬂuence
A
B
Figure 2. ExamplesofTPCgs.(A)ThisisaTPCgderivedfromthehumanprohibitingene.Theprohibitingenecontainsbothaprotein-codingregionandanRNAin
its 30-UTR (45), but only the segment of the TPCg corresponding to the protein-coding sequence is shown. In the center is an alignment of the TPCg (in red) with
prohibitin protein (in green). The graphic above it shows the position of the TPCg (red segment) in the 30-UTR of an mRNA that codes for a Zn-finger-containing
protein (blue segment). (B) An example of a TPCg that mapsto a knownglobular protein domain.The TPCg derives from the mRNA for the precursorsequence of
mitochondrial2-amino-3-ketobutyratecoenzymeA.Thedomainisfromtheclosest-matchingproteinstructure(fromE.coli,PDBcode1fc4a).IntheMolscript(54)
picture, the protein chain trace color changes at the position of each disablement. The alignment of the E.coli domain sequence and the human TPCg sequence is
shown. The part of the sequence that maps to an EST (gij6138420) is boxed and italicized.
Nucleic Acids Research, 2005, Vol. 33, No. 8 2381on the genes’ transcription and translation, through upstream
ORF formation, or the action of other undiscovered elements.
Such TPCgs could exert such effects through co-option as
alternative splicings, as has been observed for Alus (53).
Also, it is possible that some TPCgs produce a short peptide
that does not misfold or aggregate in the cell, but is still
targeted and serves an alternative function as a truncated pep-
tide. Certainly, TPCgs represent a source of transcriptional
‘noise’, which may have implications for selection pressures
on transcription levels, and the degree of variation on which
such pressures can act.
Oursurveyprovidesevidencefortheexistenceinthe human
genome of a small population of TPCgs, which are an inter-
mediate class of retrosequence derived from genes, since they
have expression evidence (like genes), but also have evidence
of lack of coding ability (like other pseudogenes). The distri-
bution of TPCgs near the 50 and 30 ends of genes indicates that
TPCgs can co-opt genic promoters or intrude into UTRs;
furthermore, this is a robust observation that veriﬁes our
expression-data mappings. One must also point out, however,
that about half of the TPCgs are located away from genes in
intergenic DNA (Table 3), and thus may be co-opting cryptic
promoters of undesignated origin. Also, TPCgs differ from
other PCgs (without transcription evidence) and from pro-
cessed genes in terms of their distribution per chromosome,
and their projected conservation in mouse. Our analysis indic-
ates that, unlike processed genes and other PCgs, the vast
majority ( 95%) of TPCgs are human lineage-speciﬁc. In
combination, the chromosomal distribution and mouse con-
servation for TPCgs suggests that there is some general evolu-
tionary pressure to delete TPCgs from the genome. One should
point out that the cDNA coverage of both genomes is far from
complete (as illustrated here, with some simple sampling
analysis), so that the analysis of conservation in mouse should
be regarded as tentative.
This TPCg analysis has important implications for genome
annotation. It is still common practice to assume that an
mRNA contains one undisrupted open reading frame; how-
ever, it is clear that one should routinely check for TPCgsi n
the manner described here. Also, this TPCg annotation is
useful for improved interpretation of microarray expression
data (22,23). The list of TPCgs is available at: http://www.
biology.mcgill.ca/faculty/harrison/tppg/tppg.tar (or) http://
pseudogene.org.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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